Insulin Detemir is a long-lasting, recombinant version of human insulin. It is an insulin analogue with myristic acid bound to the lysine at position B29 and a deletion of B30.
CAT No: 10-101-333
CAS No:169148-63-4
Chemical Name:(2S)-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-4-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-6-(tetradecanoylamino)hexanoic acid
Insulin detemir is a recombinant, long-acting insulin analog that plays a significant role in biochemical and metabolic research involving insulin signaling, glucose homeostasis, and receptor pharmacology. Structurally modified by the acylation of the B29 lysine residue with a myristic acid, this analog exhibits unique pharmacokinetic properties, including prolonged duration of action and stable absorption profiles. Its molecular design allows for reversible binding to albumin, which underpins its extended activity and differentiates it from native human insulin and other analogs. These features make insulin detemir a valuable tool for researchers investigating the mechanisms of insulin action, the regulation of carbohydrate metabolism, and the development of novel insulin formulations.
Metabolic pathway studies: Insulin detemir is extensively utilized in experimental models to elucidate insulin-mediated signaling cascades and metabolic responses. Its predictable and sustained activity profile enables precise investigation of glucose uptake, glycogen synthesis, and lipid metabolism in cultured cells, tissue explants, and animal models. Researchers leverage its unique pharmacological properties to dissect the temporal aspects of insulin action and to compare the efficacy and molecular mechanisms of different insulin analogs in metabolic regulation.
Receptor binding and pharmacodynamics: The analog's structural modifications make it particularly suited for studies focused on insulin receptor binding kinetics and downstream signaling. By providing a consistent and prolonged activation of the insulin receptor, insulin detemir facilitates detailed analyses of receptor affinity, activation thresholds, and desensitization processes. Its use in in vitro and in vivo experiments supports the differentiation of receptor-mediated effects from those induced by endogenous or short-acting insulin variants, enabling more accurate modeling of insulin pharmacodynamics.
Formulation and delivery research: Insulin detemir is a key reference compound in the development and optimization of extended-release insulin formulations. Its acylation-driven albumin binding serves as a model for designing next-generation insulin analogs and delivery systems aimed at achieving sustained pharmacological effects. Scientists and formulation chemists employ it to evaluate the impact of molecular modifications on solubility, aggregation behavior, and subcutaneous absorption, thereby informing the rational design of improved insulin-based therapeutics for research purposes.
Comparative analog studies: The compound's well-characterized profile makes it an essential standard for comparative studies involving other long-acting or rapid-acting insulin analogs. By serving as a benchmark, insulin detemir allows researchers to systematically assess differences in duration of action, metabolic outcomes, and receptor activation patterns. Such comparative analyses are critical for advancing the understanding of structure-activity relationships within the insulin analog class and for guiding the selection of optimal analogs for specific experimental protocols.
Analytical assay development: Insulin detemir is frequently incorporated into the validation and calibration of analytical assays designed to quantify insulin analogs in biological matrices. Its distinct molecular signature and stability profile facilitate the development of sensitive and specific immunoassays, chromatographic methods, and mass spectrometry protocols. These analytical tools are indispensable for monitoring pharmacokinetics, assessing bioavailability, and supporting quality control in research environments focused on insulin biology and analog development.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More